0
0
Read Time:10 Minute, 24 Second
The Continuous Bioprocessing Market is projected to reach $1.32 billion by 2031, at a CAGR of 19.6% during the forecast period, says Meticulous Research®. Continuous bioprocessing is a single-unit operation in biomanufacturing where raw materials are processed in a single unit to obtain the final product. The primary aim of continuous bioprocessing is to reduce the manufacturing cost, increase the output of the manufacturing facilities, and intensify the manufacturing of biopharmaceuticals. Continuous bioprocessing is employed in the commercial manufacturing of monoclonal antibodies (mAb), cell & gene therapies, vaccines, and recombinant proteins.
The growth of the continuous bioprocessing market is driven by the rising demand for biopharmaceuticals, the emergence of continuous end-to-end bioprocessing, global initiatives supporting the adoption of biopharmaceuticals, and the advantages of continuous manufacturing over fed-batch processes. However, high capital investment requirements and operational complexities in continuous bioprocessing restrain the growth of this market.
Furthermore, Bioprocessing 4.0 and the increasing use of continuous bioprocessing for monoclonal antibody production are expected to generate growth opportunities for the stakeholders in this market. However, cross-contamination risks and process development control are major challenges impacting market growth.
Here are the top 10 companies operating in the Continuous Bioprocessing Market
Founded in 1902 and headquartered in Minnesota, U.S., 3M is a multinational conglomerate with expertise in product development, manufacturing, and marketing across various industries, such as consumer care, industrial safety, and healthcare. The company manages its operations across four business segments: Transportation and Electronics, Safety and Industrial, Consumer, and Health Care.
The Health Care business segment offers oral care solutions, medical solutions, health information systems, separation and purification sciences, food safety, and drug delivery systems. Separation and purification sciences include a comprehensive range of filtration products intended for the separation, classification, and purification of gases and fluids. The company provides a range of chromatography filters for biopharmaceutical applications such as vaccines, recombinant proteins, chemical pharmaceuticals, and plasma fractionation.
3M sells its products through a number of distribution channels, including numerous ecommerce, retailers, traditional wholesalers, dealers, distributors, and directly to users. The company operates 64 manufacturing facilities across 29 states of the U.S. and has over 97 manufacturing and converting facilities in 35 countries.
Thermo Fisher Scientific Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific, Inc. is a biotechnology company primarily engaged in supporting life sciences research, solving complex analytical challenges, improving patient diagnostics, and increasing laboratory productivity. The company operates through its four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
The company’s life science segment consists of bioscience, genetic sciences, clinical next-generation sequencing, and bioproduction. The company’s bioproduction offerings include single-use bioproduction solutions, production cell culture media solutions, chromatography products, rapid molecular products, and scalable solutions for the manufacturing of cell therapy-based drugs.
The company sells and markets its products and services through electronic commerce, direct sales force, third-party distributors, and customer service professionals. The company serves over 400,000 customers working in the biotech and pharma space, diagnostic labs, hospitals and clinics, research institutions, government agencies, universities, and environmental, industrial quality, and process control settings.
Founded in 1870 and headquartered in Göttingen, Germany, Sartorius AG assists biopharmaceutical research and development and manufacturing companies. The company conducts its operations through two divisions: Lab Product and Services and Bioprocess Solutions. The Bioprocess Solutions division offers products and services for biopharma production. Some of the technologies under Bioprocess Solutions include cell line technologies, bioreactors, cell culture media, products for separation, purification, and concentration, and storage and transportation of products.
The company markets its products directly through sales representatives. In 2012, it expanded its direct sales operations in Asia-Pacific by acquiring a sales partner in Taiwan, particularly from Bioprocess Solutions. The company’s Bioprocess Solutions segment has a well-developed production network, with the largest production sites located across France, Germany, and Puerto Rico. The company also manufactures in Switzerland, India, the U.K., Tunisia, and the U.S.
Eppendorf AG (U.S.)
Founded in 1945 and headquartered in Hamburg, Germany, Eppendorf AG is a life science company involved in the manufacturing and selling of laboratory instruments, consumables, and services. The company operates in four business segments: Separation & Instrumentation, Consumables, Liquid Handling, and Lab Solutions, under which it manufactures and sells products like manual and automatic pipettes, centrifuges, dispensers, spectrometers, mixers, DNA amplification equipment, fermenters and bioreactors, ultra-low temperature freezers, shakers, CO2 incubators, cell manipulation systems, single-use bioreactor systems and consumables like test tubes, microtiter plates, and pipette tips. The company has a direct presence in about 26 countries and other international markets through distributors.
Founded in 1948 and headquartered in Washington, D.C., U.S., Danaher Corporation provides continuous bioprocessing products through its subsidiaries, Pall Corporation and Cytiva.
Pall Corporation is a manufacturer of high-tech separation, filtration, and purification instruments serving diverse needs of customers for various application industries. Pall Life Sciences and Pall Industrial are the primary operating segments of the company. The company’s life sciences business provides products and services that support the discovery, development, and production of medicinal products, including vaccines, biotech drugs, cell therapies, and pharmaceuticals. The life sciences offerings include depth filtration, sterile filtration, chromatography hardware, purification platform, and bio containers. The company is present across 80 locations worldwide.
Cytiva is a provider of services and technologies to advance and accelerate the development and production of therapeutics. The company offers its solutions for bioprocessing, cellular analysis, cell and gene therapy, diagnostics, enterprise solutions, genomics, lab filtration, and protein research. The company’s portfolio of bioprocessing solutions consists of upstream and downstream bioprocessing, enterprise solutions for bioprocessing, and fast-track bioprocessing services. Upstream and downstream bioprocessing involves solutions for improving Xcellerex bioreactors, HyClone cell culture media, MabSelect chromatography resins, and ÄKTA systems. Enterprise solutions for bioprocessing involve KUBio facilities and Modular FlexFactory platforms for integrated platforms. FastTrack bioprocessing services include process development, collaborative training, and manufacturing services. Cytiva has its presence across 40 locations covering North America, Europe, Asia, Latin America, and the Middle East, and Africa.
Meticulous Research in its latest publication on Continuous Bioprocessing Market has predicted the growth of 19.6% during the forecast year 2024-2031.
Merck KGaA (Germany)
Founded in 1981 and headquartered in Darmstadt, Germany., Merck KGaA is a science and technology company aimed to improve the health and well-being of people and advance their lives through science and technology. The company operates its business through three segments: Healthcare, Life Sciences, and Performance Materials.
The Life Sciences business segment is further categorized into Research Solutions, Process Solutions, and Applied Solutions. Process solutions provide drug manufacturers with process development technologies and expertise, including continuous bioprocessing. The company operates in the continuous bioprocessing market through its Process Solutions business unit (a part of the Life Sciences segment). The Life Science business sector has 59 manufacturing sites and more than 100 distribution centers worldwide.
The sector has corporate offices, manufacturing units, and distributors across Argentina, Germany, France, Romania, Colombia, Japan, Brazil, Belgium, Croatia, the U.S., and Iraq, among others. The company’s life science segment serves various clients catered across a range of geographies, namely, North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Some of its subsidiaries operating in the continuous bioprocessing market include Merck Life Science S.r.l. (Italy), Merck Life Science S.L.U. (Spain), Merck Chemicals and Life Science AB (Sweden), Merck Life Science UK Limited, Merck Life Science Ltd. (China), Merck Life Science Pvt. Ltd. (India), Merck S.A. (Brazil), and Merck, S.A. de C.V. (Mexico).
Founded in 1981 and headquartered in Massachusetts, U.S., Repligen Corporation is a global life sciences company specializing in the development and commercialization of innovative bioprocessing technologies and systems, increasing flexibility and efficiencies in biologics manufacturing. The company’s bioprocessing business involves four main franchises: Filtration, Chromatography, Process Analytics, and Proteins.
The chromatography franchise includes products for development, downstream purification, manufacturing, and quality control of biologics. The company entered the filtration technology market in 2014 after the acquisition of XCell Alternating Tangential Flow (“ATF”) assets from Refine Technology LLC (U.S.), which have applications in continuous cell culture processing. The company also has a portfolio of process analytics products complementing its product offering. Furthermore, through the proteins segment, the company assists upstream bioprocessing.
The company’s bioprocessing products are majorly sold to biopharmaceutical development companies, life sciences companies, and contract manufacturing organizations. The company’s manufacturing facilities are located in Waltham, Massachusetts; Rancho Dominguez, Marlborough, Massachusetts, Texas; California; Irving, Lund, Sweden; Bridgewater, New Jersey; and Weingarten, Germany.
Getinge AB (Sweden)
Founded in 1904 and headquartered in Gothenburg, Sweden. Getinge AB offers continuous bioprocessing products through its acquired company, Applikon Biotechnology.
Applikon Biotechnology develops and supplies advanced bioreactor systems from lab scale to pilot and production scale. The company supports the pharmaceutical industry and industrial microbiology in upstream processing by implementing scalable platforms from initial screening through full-scale development. The company offers cultivation systems, process controls, software, turnkey systems, process analytics, perfusion, and integrated solutions for various industries, such as biofuels, pharma, regenerative medicine, academia, and food.
The company’s Applikon BioSep System is a cell retention device for high-quality perfusion processes. It uses a high-frequency resonant ultrasonic wave for cell separation instead of a physical membrane or mesh. The company underwent facility expansion and currently has a global distribution network covering over 35 countries.
Incorporated in 1999 and headquartered in Mercia, Spain, Bionet is a manufacturer of laboratory, pilot, and industrial equipment and software for the bioprocessing industry. The company also provides bioprocess-related services for companies that produce biomolecules through cell culturing and microbial fermentation.
The company’s portfolio of bioprocessing solutions includes automation software solutions, bioreactors/fermenters, auxiliary equipment, such as cleaning-in-place systems, and tangential filtration. For industrial clients, the company provides complete bioproduction plants, integrating its proprietary equipment with technologies, such as centrifuges and homogenizers, from other vendors.
The company also provides services, including operation and maintenance activity, qualification, and technology election. Bionet is also part of international R&D institutions, organizations, and projects such as CETENMA, ASEBIO, CITEM, BRIDGE2020, GREENPGAS, PROGRAMA “HORIZONTE PYME”, GREEN PROTEIN, and FABRICACIÓN DEVACUNAS. The company has also been ISO 9001:2015, certified by AENOR for its quality management systems.
Corning Inc (U.S.)
Founded in 1851 and headquartered in Massachusetts, U.S., Corning Inc. manufactures its products using glass science, ceramic science, and optical physics. The company operates in semiconductor, optical communications, mobile consumer electronics, display, automotive, solar, and life sciences markets.
The company operates through five reportable segments: Environmental Technologies, Optical Communication, Specialty Materials, Life Sciences, and Display Technologies. The company provides continuous bioprocessing products through the Life Sciences segment. The Life Sciences segment provides solutions for chemicals, drugs, biologics, vaccines, and cell and gene therapies using material science, cell culture, polymer surface science, and cell biology. The Life Sciences segment offers products in the form of consumables, including liquid handling plastics, plastic vessels, specialty surfaces, cell culture media and serum, general labware, glassware, and equipment.
The company sells life sciences products under the Corning, Falcon, PYREX, and Axygen brands. Corning Inc. has its production sites for the Life sciences segment in New York, California, Illinois, Maine, Massachusetts, France, Mexico, Brazil, Poland., North Carolina, Utah, Virginia, and China. The company had 564 patents worldwide for products, technologies, and manufacturing processes under the life sciences segment. The company has a presence in India, China, Poland, Germany, France, Turkey, UAE, South Africa, and others.
Some of the other players operating in the global continuous bioprocessing market are Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), Adolf Kühner AG (Switzerland), Esco Lifesciences (Singapore), SATAKE MultiMix Corporation (Japan), Stobbe Group (Switzerland), bbi-biotech GmbH (Germany), OmniBRx Biotechnologies Private Limited (India), Solida Biotechnology GmbH (Germany), and Meissner Corporation (U.S.).
Authoritative Research on the Continuous Bioprocessing Market – Global Opportunity Analysis and Industry Forecast (2024-2031)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
